DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) is a phase 3 interventional study registered as NCT05566795 by Day One Biopharmaceuticals, Inc., with 418 participants enrolled, started 2023-02-27 and due to reach its primary completion in 2027-06. Interventions recorded: Tovorafenib and Chemotherapeutic Agent.